Tag Archives: Cardiorentis

December, 2015

  • 11 December

    Cardiorentis’ ADHF Drug Receives Fast Track Status from the FDA

    ZUG, Switzerland, Dec. 11, 2015 /PRNewswire/ — Cardiorentis AG, a privately held biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track status to Ularitide, an investigational therapy for the treatment of acute decompensated heart failure (ADHF). The FDA’s Fast Track process is intended …